CN106806885A - 一种中西医治疗肺癌的药物及其制备方法 - Google Patents
一种中西医治疗肺癌的药物及其制备方法 Download PDFInfo
- Publication number
- CN106806885A CN106806885A CN201510863249.XA CN201510863249A CN106806885A CN 106806885 A CN106806885 A CN 106806885A CN 201510863249 A CN201510863249 A CN 201510863249A CN 106806885 A CN106806885 A CN 106806885A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- powder
- root
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 32
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 32
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 36
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 24
- 244000157790 Buglossoides arvense Species 0.000 claims abstract description 24
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 24
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 24
- 229960000479 ceftriaxone sodium Drugs 0.000 claims abstract description 18
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims abstract description 18
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 235000000336 Solanum dulcamara Nutrition 0.000 claims abstract description 16
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 16
- 241000218989 Trichosanthes Species 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 241001660870 Cyrtomium Species 0.000 claims abstract description 15
- 241000405414 Rehmannia Species 0.000 claims abstract description 15
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 15
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 15
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 15
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 15
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 14
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 13
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 13
- 241000220457 Crotalaria Species 0.000 claims abstract description 11
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 241000193241 Solanum dulcamara Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000000469 ethanolic extract Substances 0.000 claims description 10
- 239000011858 nanopowder Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229910000831 Steel Inorganic materials 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000010959 steel Substances 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 230000009514 concussion Effects 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 241000282376 Panthera tigris Species 0.000 claims 1
- 108010010998 polyactin A Proteins 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 9
- 230000002588 toxic effect Effects 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 14
- 241000208365 Celastraceae Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 241000736199 Paeonia Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 208000000616 Hemoptysis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 244000061457 Solanum nigrum Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000208966 Polygala Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003238 somatosensory effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 244000028602 Crotalaria sessiliflora Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000001659 Oldenlandia diffusa Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 235000015506 Solanum lyratum Nutrition 0.000 description 1
- 241000585552 Solanum lyratum Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种中西医治疗肺癌的药物及其制备方法,该药物由下列按重量份的成分制成:20~25份的黄芪、20~30份的紫草、15~18份的半枝莲、15~20份的虎杖粉、22~25份的仙鹤草、12~15份的麦冬、20~25份的天花粉、15~20份的龙葵、3~5份的灵芝、10~12份的白英、10~15份的农吉利、10~12份的白芍、5~8份的生地、10~15份的瓜蒌、8~10份的贯众、0.5~0.8份的头孢曲松钠针剂、0.5~1份的硫酸特布他林片和1.5~2.0份的α-甘露聚糖肽。该药物能有效地治疗肺癌等肿瘤内科疾病,其服用方便、疗程短、见效快、毒副作用小且不会形成药物依赖,制备方法简单,成本低。
Description
技术领域
本发明属于中西合成药领域,具体涉及中西医治疗肺癌的药物及其制备方法。
背景技术
恶性肿瘤又称癌症,已成为威胁人类生命的常见病、多发病,为我国城市人口死亡十大病因之首。据世界卫生组织(WHO)报告,全世界癌症的发病率正以每年3%的速度递增,每年因癌症而死亡人数高达600多万人。
肺癌,是原发性支气管肺癌的简称,也是发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤之一。现代工业的蓬勃发展,在为人类带来了方便快捷的现代生活方式的同时,也对环境造成了不可逆的影响,大气中PM2.5颗粒严重超标的问题,在当前也引起了广泛关注,这些问题,导致近年来癌症发病率直线上升,但至目前为止,还没有一种有效的治疗方法。
西医主要采用的放、化疗方法,但具有一定的毒副作用,对病人造成很大的痛苦和伤害。中医治疗,主要对初、中期病人有一定的疗效,对晚期病人效果不明显,而且也有一定的毒副作用。
因此,细究癌症病因、发病流程,并寻找到一种切实有效的防治肺癌的方法,改善癌症患者的生活质量,减少复发率,降低死亡率已成为当务之急。
发明内容
为解决上述问题,克服现有技术存在的上述缺陷,本发明提供了一种中西医治疗肺癌的药物及其制备方法,该药物用药安全、疗效确切,以提高治愈率为目标,针对性强、效果显著,能有效地治疗肺癌等肿瘤内科疾病。该药物服用方便、疗程短、见效快、毒副作用小且不会形成药物依赖,制备方法简单。
本发明为解决上述技术问题所采用的技术方案是一种中西医治疗肺癌的药物,该药物由下列按重量份的成分制成:20~25份的黄芪、20~30份的紫草、15~18份的半枝莲、15~20份的虎杖粉、22~25份的仙鹤草、12~15份的麦冬、20~25份的天花粉、15~20份的龙葵、3~5份的灵芝、10~12份的白英、10~15份的农吉利、10~12份的白芍、5~8份的生地、10~15份的瓜蒌、8~10份的贯众、0.5~0.8份的头孢曲松钠针剂、0.5~1份的硫酸特布他林片和1.5~2.0份的α-甘露聚糖肽。
优选的是,该药物由下列按重量份的成分制成:22份的黄芪、25份的紫草、16份的半枝莲、18份的虎杖粉、23份的仙鹤草、14份的麦冬、22份的天花粉、18份的龙葵、4份的灵芝、11份的白英、13份的农吉利、11份的白芍、6份的生地、12份的瓜蒌、9份的贯众、0.6份的头孢曲松钠针剂、0.7份的硫酸特布他林片和1.6份的α-甘露聚糖肽。
此外,本发明提供了一种所述的中西医治疗肺癌的药物的制备方法,该制备方法包括以下步骤:
1)首先称取上述重量份的紫草、半枝莲和仙鹤草混合均匀,在60~70℃下干燥15~25分钟,边干燥边均匀搅拌;之后将上述原料放入粉碎机中粉碎成粗料过90~100目筛;加入紫草、半枝莲和仙鹤草的重量和1.8~2.2倍的质量浓度为70~75%的乙醇在50~60℃加热,回流提取3次,每次1~1.5小时,将制得的乙醇提取液,在60~65℃加热浓缩至药液浓度为0.6g生药/ml,干燥成粉,得醇提干燥粉备用;乙醇提取后的紫草、半枝莲和仙鹤草药渣备用;
2)取上述重量份的黄芪、龙葵和灵芝混合均匀,用170~200℃高温处理10~20分钟,取出冷却至室温,置入粉碎机粉碎至110~120目,然后采用超音速气流粉碎至20~40μm,用纳米球磨机研磨1~3个小时,得粒径分布为150~250nm的纳米粉备用;
3)将步骤1)中乙醇提取后的药渣和步骤2)中的纳米粉与上述重量份的农吉利、麦冬、白芍混合并粉碎均匀,加水量为上述合并原料之和的11~13倍量的水,煎煮3次,每次煎煮0.5~1.5小时,合并煎液,并用体积为10L的大孔吸附树脂柱滤过,浓缩至在70℃热测时相对密度1.05~1.07,静置1.5~2小时并喷雾干燥,得喷雾干燥粉备用;
4)将上述重量份的虎杖粉、天花粉、白英、生地、瓜蒌和贯众混合均匀后,采用超音速气流粉碎至15~25μm,再用超声萃取设备进行超声分散提取,提取时间为5~10分钟,将提取液喷雾干燥成粉末备用;
5)将上述重量份的硫酸特布他林片放入砸药罐内,用木棒把药片碾碎成为药粉,加入步骤3)和4)得到的粉末,并加入上述重量份的头孢曲松钠针剂混合均匀,于55~60℃烘干,再加入上述重量份的α-甘露聚糖肽混匀,置于钢板上冷却,粉碎成颗粒,制粒,压片即可。
在上述任一方案中优选的是,步骤2)中高温处理的温度为180℃,处理时间为15分钟。
在上述任一方案中优选的是,步骤4)中的超声功率为:1100W~1200W、超声频率:125~130KHz。
在上述任一方案中优选的是,该头孢曲松钠针剂在加入步骤5)前震荡5~10分钟。
其中,半枝莲:辛,平;功能清热解毒,活血化瘀,消肿止痛,抗癌;主治阑尾炎、肝炎、胃痛、早期肝癌、肺癌、胃癌、子宫颈癌、乳腺炎等;外用治痛疖疗,跌打肿痛等症。
灵芝:味苦性温,功能补中,益精气,能治胸中结,久服具轻身延寿之能。
黄芪:味甘,微温,具有补气固表,托疮生肌、利水的功效,主治气血虚弱、自汗等症。
天花粉:味甘;微苦;性微寒。归肺;胃经。清热生津;润肺化痰;消肿排脓。主治热病口渴;消渴多饮;肺热燥咳;疮疡肿毒。《本经逢原》载:“降膈上热痰,润心中烦渴,除时疾狂热,祛酒瘅湿黄,治痈疡解毒排脓。”现代医学研究证实,天花粉富含天花粉蛋白,有免疫刺激和免疫抑制作用,抑制病毒复制繁衍,减少免疫细胞中受病毒感染的活细胞数,能降低血糖活性,对溶血性链球菌、肺炎双球菌、白喉杆菌有一定的抑制作用。
虎杖:味苦;酸;性微寒。归肝;胆经。具有活血散瘀;祛风通络;清热利湿;解毒之功效。现代医学研究证实,具有保肝、镇咳平喘作用,虎杖提取物有解热镇痛作用。
龙葵:拉丁学名Solanum nigrum L,性味:性寒,味苦、微甘;有小毒。功效:对抗炎、血糖的影响、中枢神经、降压和对免疫功能的影响有药理作用。主治清热解毒,活血消肿。
白英:拉丁学名Solanum lyratum Thunberg,性味:苦,微寒,有小毒。功效:用治感冒发热、乳痈等,治疗湿热黄疸或腹水肿痛、小便不利者,可用于风湿痹痛,肺癌以及胃肠道癌肿等症。
农吉利:拉丁学名Crotalaria sessiliflora L,性味:苦、辛,凉。清热解毒,功效:止咳平喘,截疟,体外实验具有抗癌活性。
瓜蒌:拉丁学名Trichosanthis Kirilowii Fructus et Semen,性味:甘,苦,寒。功效:润肺,化痰,散结,润肠。治痰热咳嗽,胸痹,结胸,肺痿咳血,消渴,黄疸,便秘,痈肿初起。有益心血管系统,抗溃疡,抗菌,抗癌,抗衰老。
白英:可祛风利湿、凉血解毒。
紫草:凉血,活血,清热,解毒。治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。
仙鹤草:收敛止血,截疟,止痢,解毒。用于咳血、吐血、治流鼻血有特效、疟疾、脱力劳伤、痈肿。
麦冬:具有抗疲劳、清除自由基、提高细胞免疫功能以及降血糖的作用;有镇静、催眠、抗心肌缺血、抗心律失常、抗肿瘤等作用,尤其对增进老年人健康具有多方面功效
龙葵:苦,寒,清热,解毒,活血,消肿。用于疔疮,痈肿,丹毒,跌打扭伤,慢性咳嗽痰喘,水肿,癌肿。
白芍:平肝止痛,养血调经,敛阴止汗。用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗。
生地:具有清热凉血、益阴生津之功效。用于温热病热入营血,壮热神昏,口干舌绛。
贯众:主治风热感冒、温热癍疹、吐血、咳血、衄血。
头孢曲松钠:用于敏感菌感染的脑膜炎、肺炎、皮肤软组织感染、腹膜炎、泌尿系统感染、淋病、肝胆感染、外科创伤,败血症及生殖器感染等。
α-甘露聚糖肽:可治疗各种病毒、致病菌、可治疗反复呼吸感染、慢性支气管炎、用于治疗再生障碍性贫血、具有升白细胞和血小板作用等。可用于治疗各种肿瘤、与化疗、放疗联合治疗肺癌、胃癌、肠癌、食道癌、乳腺癌、白血病等。
硫酸特布他林:用于支气管哮喘、哮喘型支气管炎和慢性阻塞性肺部疾患时的支气管痉挛。
本发明的有益效果:
1.该中西医治疗肺癌的药物服用方便、疗程短、见效快、毒副作用小且不会形成药物依赖。
2.本发明的药物中西医结合治疗,标本兼固,发挥协同效应,促进早日康复。
3.本发明的药物有效针对病症机理,由内到外,能够达到很好的治愈目的,不伤害人体正常细胞,强化人体免疫功能,促进新陈代谢;不用手术、化疗、放疗,具有抑瘤率高、适应症广等优点。
4.该药物的制备方法简单,成本低,效率高、经济效益、社会效益显著。
上述的药物成分是经过多年验证、记载和试验所得,虽然它们的功效各异,但是每一种成分的选取都不是随意而为,本申请根据多年的试验所得各成分的配比,并不是将各成分的原料功效简单叠加,因为各种成分之间可能存在相生、相须、相畏或相杀等多种作用关系,而本申请就是根据这种原则相应的选择了上述原料,并且确定了它们之间的最佳配比,因此,本申请具有显著的意义。
具体实施方式
下面结合具体实施方式对本发明作进一步说明。
实施例1
一种中西医治疗肺癌的药物,该药物由下列按重量份的成分制成:20份的黄芪、30份的紫草、15份的半枝莲、20份的虎杖粉、22份的仙鹤草、15份的麦冬、20份的天花粉、20份的龙葵、3份的灵芝、12份的白英、10份的农吉利、12份的白芍、5份的生地、15份的瓜蒌、8份的贯众、0.8份的头孢曲松钠针剂、0.5份的硫酸特布他林片和2.0份的α-甘露聚糖肽。
所述的中西医治疗肺癌的药物的制备方法,该制备方法包括以下步骤:
1)首先称取上述重量份的紫草、半枝莲和仙鹤草混合均匀,在60℃下干燥25分钟,边干燥边均匀搅拌;之后将上述原料放入粉碎机中粉碎成粗料过90目筛;加入紫草、半枝莲和仙鹤草的重量和2.2倍的质量浓度为70%的乙醇在60℃加热,回流提取3次,每次1小时,将制得的乙醇提取液,在65℃加热浓缩至药液浓度为0.6g生药/ml,干燥成粉,得醇提干燥粉备用;乙醇提取后的紫草、半枝莲和仙鹤草药渣备用;
2)取上述重量份的黄芪、龙葵和灵芝混合均匀,用170℃高温处理20分钟,取出冷却至室温,置入粉碎机粉碎至110目,然后采用超音速气流粉碎至40μm,用纳米球磨机研磨1个小时,得粒径分布为250nm的纳米粉备用;
3)将步骤1)中乙醇提取后的药渣和步骤2)中的纳米粉与上述重量份的农吉利、麦冬、白芍混合并粉碎均匀,加水量为上述合并原料之和的11倍量的水,煎煮3次,每次煎煮1.5小时,合并煎液,并用体积为10L的大孔吸附树脂柱滤过,浓缩至在70℃热测时相对密度1.05,静置1.5~2小时并喷雾干燥,得喷雾干燥粉备用;
4)将上述重量份的虎杖粉、天花粉、白英、生地、瓜蒌和贯众混合均匀后,采用超音速气流粉碎至25μm,再用超声萃取设备进行超声分散提取,提取时间为5分钟,将提取液喷雾干燥成粉末备用;
5)将上述重量份的硫酸特布他林片放入砸药罐内,用木棒把药片碾碎成为药粉,加入步骤3)和4)得到的粉末,并加入上述重量份的头孢曲松钠针剂混合均匀,于60℃烘干,再加入上述重量份的α-甘露聚糖肽混匀,置于钢板上冷却,粉碎成颗粒,制粒,压片即可。
其中,步骤2)中高温处理的温度为180℃,处理时间为15分钟,步骤4)中的超声功率为:1100W、超声频率:130KHz,该头孢曲松钠针剂在加入步骤5)前震荡5分钟。
实施例2
一种中西医治疗肺癌的药物,该药物由下列按重量份的成分制成:25份的黄芪、20份的紫草、18份的半枝莲、15份的虎杖粉、25份的仙鹤草、12份的麦冬、25份的天花粉、15份的龙葵、5份的灵芝、10份的白英、15份的农吉利、10份的白芍、8份的生地、10份的瓜蒌、10份的贯众、0.5份的头孢曲松钠针剂、1份的硫酸特布他林片和1.5份的α-甘露聚糖肽。
所述的中西医治疗肺癌的药物的制备方法,该制备方法包括以下步骤:
1)首先称取上述重量份的紫草、半枝莲和仙鹤草混合均匀,在70℃下干燥15分钟,边干燥边均匀搅拌;之后将上述原料放入粉碎机中粉碎成粗料过100目筛;加入紫草、半枝莲和仙鹤草的重量和1.8倍的质量浓度为75%的乙醇在50℃加热,回流提取3次,每次1.5小时,将制得的乙醇提取液,在60℃加热浓缩至药液浓度为0.6g生药/ml,干燥成粉,得醇提干燥粉备用;乙醇提取后的紫草、半枝莲和仙鹤草药渣备用;
2)取上述重量份的黄芪、龙葵和灵芝混合均匀,用200℃高温处理10分钟,取出冷却至室温,置入粉碎机粉碎至120目,然后采用超音速气流粉碎至20μm,用纳米球磨机研磨3个小时,得粒径分布为150nm的纳米粉备用;
3)将步骤1)中乙醇提取后的药渣和步骤2)中的纳米粉与上述重量份的农吉利、麦冬、白芍混合并粉碎均匀,加水量为上述合并原料之和的13倍量的水,煎煮3次,每次煎煮0.5小时,合并煎液,并用体积为10L的大孔吸附树脂柱滤过,浓缩至在70℃热测时相对密度1.07,静置1.5小时并喷雾干燥,得喷雾干燥粉备用;
4)将上述重量份的虎杖粉、天花粉、白英、生地、瓜蒌和贯众混合均匀后,采用超音速气流粉碎至25μm,再用超声萃取设备进行超声分散提取,提取时间为5分钟,将提取液喷雾干燥成粉末备用;
5)将上述重量份的硫酸特布他林片放入砸药罐内,用木棒把药片碾碎成为药粉,加入步骤3)和4)得到的粉末,并加入上述重量份的头孢曲松钠针剂混合均匀,于60℃烘干,再加入上述重量份的α-甘露聚糖肽混匀,置于钢板上冷却,粉碎成颗粒,制粒,压片即可。
其中,步骤2)中高温处理的温度为180℃,处理时间为15分钟,步骤4)中的超声功率为:1200W、超声频率:125KHz,该头孢曲松钠针剂在加入步骤5)前震荡10分钟。
实施例3
一种中西医治疗肺癌的药物,该药物由下列按重量份的成分制成:22份的黄芪、25份的紫草、16份的半枝莲、18份的虎杖粉、23份的仙鹤草、14份的麦冬、22份的天花粉、18份的龙葵、4份的灵芝、11份的白英、13份的农吉利、11份的白芍、6份的生地、12份的瓜蒌、9份的贯众、0.6份的头孢曲松钠针剂、0.7份的硫酸特布他林片和1.6份的α-甘露聚糖肽。
所述的中西医治疗肺癌的药物的制备方法,该制备方法包括以下步骤:
1)首先称取上述重量份的紫草、半枝莲和仙鹤草混合均匀,在65℃下干燥20分钟,边干燥边均匀搅拌;之后将上述原料放入粉碎机中粉碎成粗料过95目筛;加入紫草、半枝莲和仙鹤草的重量和2倍的质量浓度为72%的乙醇在55℃加热,回流提取3次,每次1.2小时,将制得的乙醇提取液,在63℃加热浓缩至药液浓度为0.6g生药/ml,干燥成粉,得醇提干燥粉备用;乙醇提取后的紫草、半枝莲和仙鹤草药渣备用;
2)取上述重量份的黄芪、龙葵和灵芝混合均匀,用180℃高温处理15分钟,取出冷却至室温,置入粉碎机粉碎至115目,然后采用超音速气流粉碎至30μm,用纳米球磨机研磨2个小时,得粒径分布为200nm的纳米粉备用;
3)将步骤1)中乙醇提取后的药渣和步骤2)中的纳米粉与上述重量份的农吉利、麦冬、白芍混合并粉碎均匀,加水量为上述合并原料之和的12倍量的水,煎煮3次,每次煎煮1小时,合并煎液,并用体积为10L的大孔吸附树脂柱滤过,浓缩至在70℃热测时相对密度1.06,静置1.7小时并喷雾干燥,得喷雾干燥粉备用;
4)将上述重量份的虎杖粉、天花粉、白英、生地、瓜蒌和贯众混合均匀后,采用超音速气流粉碎至20μm,再用超声萃取设备进行超声分散提取,提取时间为9分钟,将提取液喷雾干燥成粉末备用;
5)将上述重量份的硫酸特布他林片放入砸药罐内,用木棒把药片碾碎成为药粉,加入步骤3)和4)得到的粉末,并加入上述重量份的头孢曲松钠针剂混合均匀,于58℃烘干,再加入上述重量份的α-甘露聚糖肽混匀,置于钢板上冷却,粉碎成颗粒,制粒,压片即可。
其中,步骤2)中高温处理的温度为180℃,处理时间为15分钟,步骤4)中的超声功率为:1150W、超声频率:128KHz,该头孢曲松钠针剂在加入步骤5)前震荡8分钟。
试验研究
本发明的药物经安全性毒理学试验表明:LD50为9000mg/kg,安全性毒理学评价为实际无毒级,无毒副作用。
急性毒性试验
将上述实验样品制成混悬液,以相当于临床日用剂量370倍的剂量对小鼠灌胃给药,在观察期间,未发现动物有任何毒性反应。给药20天观察,无一只动物死亡;动物处死后解剖,其脏器观察无明显异常。实验表明,灌胃给药测不出本发明的半数致死量,动物试验的耐受量为临床成人每天最大药量的200倍。
动物长期毒性试验
将上述样品以临床日用剂量5倍、20倍、60倍供大鼠5~6个月长期给药,两剂量组大鼠药后的一般活动,精神状态、毛发、粪便等均未见明显异常;给药前后外周血象,包括红细胞、白细胞及分类、血红蛋白、红细胞压积均在正常范围内波动;对肝、肾功能指标均未见明显影响;试验结束时动物血清中总蛋白、白蛋白、碱性磷酸酶的含量与对照组相比无明显差异;心电图检查均未发现异常;各主要脏器肉眼检查未见明显肿大、充血、坏死等病理形态学变化;心、肝、脾、肺、肾、胸腺、肾上腺等器官的重量系数与对照组相比无显著差异;病理组织学检查均未见异常。以上结果说明本发明比较安全,在所试剂量范围内无明显毒副作用。
主要药效学实验:
检品名称:实施例1~3药物制剂。
实验动物:白鼠,体重2.6~3.0kg,健康无癌疾。
试验前24小时脊柱两侧剪毛(3cm×3cm)备皮。
实验方法:取受试物0.2m2用检品(未稀释)直接注射入一侧备皮处,一层油纸覆盖纱布、胶布固定。备皮另一侧以蒸馏水作对照。4小时后温水洗净,于2小时、20小时、40小时和80小时观察,按《药品安全评价程序和方法》中的“癌细胞刺激反应积分”,记录癌细胞刺激反应。
实验结果:按《药品安全评价程序和方法》中的“癌细胞刺激强度评价”。各观察时间未见到正常局部细胞刺激反应,正常细胞刺激反应积分为零。
为加强该药物的效果,还可在上述成分中再加入重量份为12~15份的白花蛇舌草和15~20份的远志。将白花蛇舌草、远志在60℃下干燥60分钟,边干燥边均匀搅拌,之后用粉碎机粉碎成细料过180目筛,然后直接将过180目筛的细料与上述虎杖粉、天花粉、白英、生地、瓜蒌和贯众一起在步骤4)中混合。
临床实践
病例1:陈某,女,67岁,诊断为肺癌晚期,并已转移到两腋下面,经医院实施进行化疗、放疗后,受伤害正常细胞过多,身体极度虚弱,难以进食。服用本发明药物治疗30天后,身体恢复很快,食欲正常,活动力恢复,经医院作相关检查,癌细胞得到控制。
病例2:秦某,男,51岁,患肺癌。只能进行保守疗法,主要症状为咳嗽、气喘、无法平卧、胸痛。后服用本发明的药物组合物,两个疗程后,主要症状都有所改善,患者自觉胃纳好,呼吸通顺,现在继续使用本发明之药物进行治疗。
另外还用该药物做了专门的临床研究。
按照肿瘤的诊断分为早期、中期、晚期,确定疗效评价,分为完全治愈、基本治愈、好转、无效。
完全治愈:经过半年、一年以上治疗,经医院身体检查无异常,自觉身体感觉无异常。
基本治愈:经过三个月、半年、一年以上的治疗,经医院检查无异常,自觉身体感觉仍有疼痛。
好转:经过半年、一年以上的治疗,经医院身体检查,包块变小,正在缓慢恢复。
无效:经过半年、一年以上治疗,经医院身体检查,肿瘤逐渐长大,自觉身体感觉疼痛加剧。
随机选择120例,所有病例均符合肺癌的诊断标准。年龄60~78岁,病程3~5年。
治疗方法:服用本发明所述药物(片剂),每次10~15克,每日两次,3~4个月为一个疗程,可连服两个疗程。
结果:疗效判定标准,按肺癌的疗效判定标准判定。痊愈100例,好转14例,无效6例,总有效率95%。病情诊断均采信正规医院出具的医生诊断。
本发明的中西医治疗肺癌的药物服用方便、疗程短、见效快、毒副作用小且不会形成药物依赖。其中西医结合治疗,标本兼固,发挥协同效应,促进早日康复。本发明的药物有效针对病症机理,由内到外,能够达到很好的治愈目的,不伤害人体正常细胞,强化人体免疫功能,促进新陈代谢;不用手术、化疗、放疗,具有抑瘤率高、适应症广等优点。此外,该药物的制备方法简单,成本低,效率高、经济效益、社会效益显著。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (6)
1.一种中西医治疗肺癌的药物,其特征在于该药物由下列按重量份的成分制成:20~25份的黄芪、20~30份的紫草、15~18份的半枝莲、15~20份的虎杖粉、22~25份的仙鹤草、12~15份的麦冬、20~25份的天花粉、15~20份的龙葵、3~5份的灵芝、10~12份的白英、10~15份的农吉利、10~12份的白芍、5~8份的生地、10~15份的瓜蒌、8~10份的贯众、0.5~0.8份的头孢曲松钠针剂、0.5~1份的硫酸特布他林片和1.5~2.0份的α-甘露聚糖肽。
2.根据权利要求1所述的中西医治疗肺癌的药物,其特征在于该药物由下列按重量份的成分制成:22份的黄芪、25份的紫草、16份的半枝莲、18份的虎杖粉、23份的仙鹤草、14份的麦冬、22份的天花粉、18份的龙葵、4份的灵芝、11份的白英、13份的农吉利、11份的白芍、6份的生地、12份的瓜蒌、9份的贯众、0.6份的头孢曲松钠针剂、0.7份的硫酸特布他林片和1.6份的α-甘露聚糖肽。
3.一种根据权利要求1或2所述的中西医治疗肺癌药物的制备方法,其特征在于该制备方法包括以下步骤::
1)首先称取上述重量份的紫草、半枝莲和仙鹤草混合均匀,在60~70℃下干燥15~25分钟,边干燥边均匀搅拌;之后将上述原料放入粉碎机中粉碎成粗料过90~100目筛;加入紫草、半枝莲和仙鹤草的重量和1.8~2.2倍的质量浓度为70~75%的乙醇在50~60℃加热,回流提取3次,每次1~1.5小时,将制得的乙醇提取液,在60~65℃加热浓缩至药液浓度为0.6g生药/ml,干燥成粉,得醇提干燥粉备用;乙醇提取后的紫草、半枝莲和仙鹤草药渣备用;
2)取上述重量份的黄芪、龙葵和灵芝混合均匀,用170~200℃高温处理10~20分钟,取出冷却至室温,置入粉碎机粉碎至110~120目,然后采用超音速气流粉碎至20~40μm,用纳米球磨机研磨1~3个小时,得粒径分布为150~250nm的纳米粉备用;
3)将步骤1)中乙醇提取后的药渣和步骤2)中的纳米粉与上述重量份的农吉利、麦冬、白芍混合并粉碎均匀,加水量为上述合并原料之和的11~13倍量的水,煎煮3次,每次煎煮0.5~1.5小时,合并煎液,并用体积为10L的大孔吸附树脂柱滤过,浓缩至在70℃热测时相对密度1.05~1.07,静置1.5~2小时并喷雾干燥,得喷雾干燥粉备用;
4)将上述重量份的虎杖粉、天花粉、白英、生地、瓜蒌和贯众混合均匀后,采用超音速气流粉碎至15~25μm,再用超声萃取设备进行超声分散提取,提取时间为5~10分钟,将提取液喷雾干燥成粉末备用;
5)将上述重量份的硫酸特布他林片放入砸药罐内,用木棒把药片碾碎成为药粉,加入步骤3)和4)得到的粉末,并加入上述重量份的头孢曲松钠针剂混合均匀,于55~60℃烘干,再加入上述重量份的α-甘露聚糖肽混匀,置于钢板上冷却,粉碎成颗粒,制粒,压片即可。
4.根据权利要求3所述的中西医治疗肺癌药物的制备方法,其特征在于步骤2)中高温处理的温度为180℃,处理时间为15分钟。
5.根据权利要求3或4所述的中西医治疗肺癌药物的制备方法,其特征在于步骤4)中的超声功率为:1100W~1200W、超声频率:125~130KHz。
6.根据权利要求5所述的中西医治疗肺癌药物的制备方法,其特征在于该头孢曲松钠针剂在加入步骤5)前震荡5~10分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510863249.XA CN106806885A (zh) | 2015-11-30 | 2015-11-30 | 一种中西医治疗肺癌的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510863249.XA CN106806885A (zh) | 2015-11-30 | 2015-11-30 | 一种中西医治疗肺癌的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106806885A true CN106806885A (zh) | 2017-06-09 |
Family
ID=59108271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510863249.XA Pending CN106806885A (zh) | 2015-11-30 | 2015-11-30 | 一种中西医治疗肺癌的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106806885A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269169A (zh) * | 2008-05-20 | 2008-09-24 | 江南大学 | 一种用于治疗肿瘤的中药组合物及其制备方法和应用 |
CN102114103A (zh) * | 2010-04-21 | 2011-07-06 | 胡海舰 | 一种治疗肺癌的中药口服汤剂 |
CN102283988A (zh) * | 2010-08-10 | 2011-12-21 | 王义善 | 一种可增强患者抗肿瘤活性的中药及其浸提液制备方法 |
CN104225202A (zh) * | 2013-06-13 | 2014-12-24 | 贾书超 | 一种治疗肺癌的中药方剂 |
CN104547313A (zh) * | 2013-10-12 | 2015-04-29 | 刘长源 | 一种治疗肺癌、乳腺癌、淋巴癌的药物及制备方法 |
CN104721594A (zh) * | 2015-04-07 | 2015-06-24 | 赵克俊 | 一种治疗脑外伤反应综合症的中药 |
-
2015
- 2015-11-30 CN CN201510863249.XA patent/CN106806885A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269169A (zh) * | 2008-05-20 | 2008-09-24 | 江南大学 | 一种用于治疗肿瘤的中药组合物及其制备方法和应用 |
CN102114103A (zh) * | 2010-04-21 | 2011-07-06 | 胡海舰 | 一种治疗肺癌的中药口服汤剂 |
CN102283988A (zh) * | 2010-08-10 | 2011-12-21 | 王义善 | 一种可增强患者抗肿瘤活性的中药及其浸提液制备方法 |
CN104225202A (zh) * | 2013-06-13 | 2014-12-24 | 贾书超 | 一种治疗肺癌的中药方剂 |
CN104547313A (zh) * | 2013-10-12 | 2015-04-29 | 刘长源 | 一种治疗肺癌、乳腺癌、淋巴癌的药物及制备方法 |
CN104721594A (zh) * | 2015-04-07 | 2015-06-24 | 赵克俊 | 一种治疗脑外伤反应综合症的中药 |
Non-Patent Citations (8)
Title |
---|
中国执业医师协会组织: "《全国执业药师继续教育教材》", 30 April 2007 * |
史宗道等: "《口腔临床医药学》", 30 June 2012 * |
张培彤等: ""中晚期非小细胞肺癌中西医疗效评价方法比较研究"", 《第十一届全国中西医结合肿瘤学术大会论文集》 * |
范传玲等: "《常见消化系统肿瘤诊疗护理新进展》", 31 August 2006 * |
赵春杰等: "《药学综合知识与技能》", 31 January 2014 * |
郑心等: ""中西医结合治疗肺癌优势"", 《山东中西医结合学会呼吸病专业委员会第二届学术交流会论文集》 * |
郑筱萸等: "《中国新药临床研究指导原则(试行)》", 31 May 2002 * |
陈萍等: ""中西医结合治疗晚期非小细胞肺癌"", 《长春中医药大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078473B (zh) | 一种治疗慢性乙型肝炎的中药制剂及其制备方法 | |
CN101632827B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN102198262A (zh) | 一种治疗小儿轮状病毒性肠炎的中药制剂及其制备方法 | |
CN104436018A (zh) | 治疗肿瘤的药物及其制备方法 | |
CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN103055285B (zh) | 治疗早期肝硬化的中药及其制备方法 | |
CN107913370A (zh) | 一种中西医结合治疗酒精性肝病的药物及制备方法 | |
CN102847061B (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN100467018C (zh) | 金莲清热胶囊 | |
CN102772747B (zh) | 一种治疗热毒侵心型病毒性心肌炎的中药制剂 | |
CN102198261B (zh) | 一种治疗老年慢性结肠炎的中药制剂及其制备方法 | |
CN106334171B (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
CN103652490A (zh) | 用于治疗猪蓝耳病的猪饲料及其制备方法 | |
CN106806885A (zh) | 一种中西医治疗肺癌的药物及其制备方法 | |
CN104352984A (zh) | 一种适用于热毒炽盛型的肺抑瘤膏及其制备方法 | |
CN104524461A (zh) | 一种治疗心肌炎的药物组合物及其应用 | |
CN105194165B (zh) | 一种用于泌尿系统感染的中药及制备方法 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN104524529A (zh) | 用于治疗痰热雍肺型肺炎链球菌肺炎的药物及其制备方法 | |
CN105596929A (zh) | 用于治疗痰热壅盛证型的慢性咳嗽的中药制剂的制备方法 | |
CN105920436A (zh) | 一种用于治疗肺癌的药物制剂及其制备方法 | |
CN105288285A (zh) | 一种用于治疗慢性支气管炎的药物制剂 | |
CN105106764A (zh) | 一种用于治疗妊娠呕吐的药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170609 |